Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naftopidil vs Tamsulosin in Benign Prostatic Hyperplasia
NCT01203371Phase 3Withdrawn
- Sponsor
- Apsen Farmacêutica
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naftopidil in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Apsen Farmacêutica. Primary endpoint: International Prostate Symptom Score at 12 weeks. Planned start Jan 2011; status: withdrawn.
02
Drugs
naftopidil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01203371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203371.